Skip to main content
. 2016 Jun 21;11(6):e0157509. doi: 10.1371/journal.pone.0157509

Fig 8. Relationship between trelagliptin pharmacokinetics and pharmacodynamics in T2DM patients in phase 2 dose-ranging study.

Fig 8

Observed value plotted in “X” and predicted relationship between pharmacokinetics and pharmacodynamics by sigmoid Emax model is indicated by solid line. The plasma trelagliptin concentration estimated to yield 70% and 80% inhibition of human plasma DPP-4 activity was 2.31 ng/mL and 3.13 ng/mL, respectively.